MW-C02

MW-C02 is a novel antibody-drug conjugate (ADC) developed by Mabwell, designed to target Claudin 1 (CLDN1), a tight junction protein that is overexpressed in various solid tumors. The drug leverages Mabwell's proprietary site-specific conjugation technology platform (IDDC™) and incorporates an innovative cytotoxic payload, MF6, based on the Mtoxin™ platform. Preclinical studies have demonstrated that MW-C02 exhibits robust binding to CLDN1-positive cancer cells, rapid internalization, potent cytotoxicity, and significant anti-tumor activity in both cell-derived xenograft (CDX) and patient-derived xenograft (PDX) models. The ADC also shows favorable pharmacokinetic and safety profiles in primates. Its mechanism of action involves targeted delivery of the cytotoxic payload to CLDN1-expressing tumor cells, leading to selective tumor cell death while sparing normal tissues[4].